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(HCT) and solid organ transplantation (SOT) has occurred on
many fronts. From an immunologic perspective the 2 disci-
plines share common obstacles (histoincompatibility) and
goals (immunologic tolerance). The induction of donor-
speciﬁc tolerance has been deﬁned by the lack of a destruc-
tive immune response after transplantation in the absence
of systemic immunosuppression and by the preservation
of host third-party immunity. One postulated mechanism of
tolerance induction was through mixed hematopoietic
chimerism. This mechanism was based on observations by
Owen [1] and subsequently Billingham et al. [2] that Free-
martin bovine twins sharing a common placenta developed a
naturally occurring in utero state of mixed hematopoietic
chimerism and were tolerant to skin grafts from their twin
siblings while rejecting skin grafts from nontwin cattle
during adulthood. Another postulated mechanism of toler-
ance induction was the observation that kidney transplants
have been accepted without the need for systemic immu-
nosuppression among patients who had received previous
bone marrow transplants from the same donor [3]. There are
numerous case reports (which have been summarized in
prior reviews [4,5]) of patients receiving both HCTs and SOTs,
including patients who received an HCT followed by an SOT
for a different condition and conversely those who received
an SOT followed by an HCT for either aplastic anemia or a
hematologic malignancy. Tolerance has been induced after
combined bone marrow and kidney transplants with the
intentional induction of transient mixed or full donor he-
matopoietic chimerism in patients with and without an
underlying malignancy [6-9]. Finally, planned sequential
(tandem) transplants have been reported for patients with
systemic amyloid light-chain (AL) amyloidosis with cardiac
involvement with autologous HCT performed after heart
transplantation to induce a durable remission of the
amyloidosis [10-12].
In this issue of the journal, Doney and colleagues [13]
from the Fred Hutchinson Cancer Research Center (FHCRC)
reviewed the outcomes of 40 (13 autologous and 27 alloge-
neic) previously reported patients who received an HCT after
an SOT and summarized in greater detail the outcomes of 16
(8 autologous and 8 allogeneic) additional patients trans-
planted at their institution who had an SOT after a previous
HCT. Although 12 patients were described in previous
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1083-8791/ 2015 American Society for Blood andMarrow Transplantation.reviews of patients undergoing both HCT and SOT, this is the
largest reported series of patients undergoing HCT after SOT
and is the most contemporary review of such patients.
The review by Doney et al. is thus important in showing
that the survival probability of patients who underwent SOT
followed by HCT is favorable among a select but diverse
group of patients by virtue of diagnosis, donor source, and
indication for the transplants. The more current nature of
many patients raises the possibility of improved outcomes
because of better supportive care of patients with comor-
bidities related to their previous SOT. The lessons from these
cases are clearly different according to whether the subse-
quent HCT was an autologous versus an allogeneic trans-
plant. With the autologous transplants that were described,
the capacity to toleratemyeloablative doses of chemotherapy
with hematopoietic progenitor cells serving a rescue func-
tion to circumvent the myeloablative effects of the chemo-
therapy and the achievement of durable antitumor responses
in some cases are the primary lessons. In the review of pre-
viously reported autologous HCT patients, 12 of 13 patients
were alive from .5 to 5 years after the transplant. Of the 8
FHCRC patients who underwent autologous HCT, 7 had post-
transplant lymphoproliferative disorder as the indication for
the transplant. No transplant-related mortality was reported,
and 5 patients were alive at last contact.
Among recipients of allogeneic HCT after SOT, 3 of 27
previously reported patients experienced hematopoietic
graft failure or graft rejection. Thirteen of 20 patients who
received an HCT from a related donor had an HLA-matched
sibling donor. Nineteen of 27 patients were alive from .3 to
8 years after HCT. There were 8 deaths between .1 and 1 year
after HCT, with infection as the most frequent cause of death.
The authors also reported the outcomes of 8 FHCRC patients
who received an allogeneic HCT after a prior SOT for a variety
of hematologic malignancies. For 6 of these patients, solid-
organ HLA typing was available, and the degree of HLA
mismatch varied from 3 to 7 antigens. Four patients were
alive at last contact, and 4 had succumbed to relapse of the
hematologic malignancy. Only 1 patient experienced kidney
allograft rejection.
The immunologic consequences of SOT followed by allo-
geneic HCT are both profound and intriguing. The experi-
mental and clinical observations of speciﬁc tolerance after
naturally occurring or induced states of mixed or full donor
hematopoietic chimerism before or in conjunction with an
SOT have been well described. The immunologic impact of
performing an HCT from the same donor as the previous SOT
has been less well characterized. Two reports, however,
described severe graft-versus-host disease (fatal in 1 case) in
2 patients who received an HLA-matched related donor HCT
years after a kidney transplant from the same donor, raising
the possibility that graft-versus-host alloreactivity was
relatively unopposed in these patients who had achieved
host-versus-graft tolerance [14,15]. Another more theoretical
consequence of HCT after SOT is a “graft-versus-graft effect”
when there is histoincompatibility between the solid organ
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Reassuringly, there was only 1 instance of organ graft
rejection among the 8 FHCRC patients, and it is unclear
whether this was the result of such a graft-versus-graft
effect.
Although the review by Doney et al. [13] has contributed
important new information to our understanding of the
outcomes of patients who undergo HCT after a previous SOT,
several limitations of the data exist. In all likelihood, suc-
cessful outcomes have been reported in preference to un-
successful transplants, resulting in a higher estimation of the
probability of survival than has actually occurred among
patients who have received both transplants. This literature
reporting bias is somewhat mitigated by the report of 16
patients who received both SOT and HCT at the FHCRC, but
the number of patients and the diversity of diagnoses, time
between transplants, and indications for transplant limit the
conclusions that can be reached about the general applica-
bility of this treatment strategy.
It is now quite clear that performing HCTafter prior SOT is
feasible in a select group of patients who are believed to be
medically “ﬁt” to undergo the subsequent HCT. Given the
literature reporting bias from prior case reports and the
small number of patients who have received HCT after SOT, it
would be incorrect, however, to assume that these patients
do not have a higher risk of transplant-related morbidity and
mortality, and further studies are necessary to better deﬁne
the optimal medical eligibility criteria (perhaps via a modi-
ﬁed comorbidity index) for HCT after SOT and the optimal
timing of and donor hematopoietic progenitor cell source for
the transplants.
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